PTEN inhibits BMI1 function independently of its phosphatase activity

Molecular Cancer

Volumn 8, Issue , 2009, Pages 98-

  Fan, Catherine ^a,b   He, Lizhi ^a,b   Kapoor, Anil ^a   Rybak, Adrian P ^a,b   De Melo, Jason ^a,b   Cutz, Jean Claude ^a   Tang, Damu ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE FUNCTION; GENE INACTIVATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; PROMOTER REGION; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AMINO ACIDS; CELL LINE, TUMOR; CELL NUCLEUS; ENZYME ACTIVATION; HUMANS; MALE; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; REPRESSOR PROTEINS; TELOMERASE;

EID: 70749128265     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-98     Document Type: Article

References (52)

1. Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL, Morrison SJ, Clarke MF. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003, 423:302-305. 10.1038/nature01587, 12714971.
2. Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, Morrison SJ. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 2003, 425:962-967. 2614897, 14574365, 10.1038/nature02060.
3. Bruggeman SW, Valk-Lingbeek ME, Stoop PP, Jacobs JJ, Kieboom K, Tanger E, Hulsman D, Leung C, Arsenijevic Y, Marino S, van Lohuizen M. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev 2005, 19:1438-1443. 1151660, 15964995, 10.1101/gad.1299305.
4. Molofsky AV, He S, Bydon M, Morrison SJ, Pardal R. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev 2005, 19:1432-1437. 1151659, 15964994, 10.1101/gad.1299505.
5. Chagraoui J, Niessen SL, Lessard J, Girard S, Coulombe P, Sauvageau M, Meloche S, Sauvageau G. E4F1: a novel candidate factor for mediating BMI1 function in primitive hematopoietic cells. Genes Dev 2006, 20:2110-2120. 1536061, 16882984, 10.1101/gad.1453406.
6. Akala OO, Park IK, Qian D, Pihalja M, Becker MW, Clarke MF. Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/- multipotent progenitors. Nature 2008, 453:228-232. 10.1038/nature06869, 18418377.
7. Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell 1991, 65:753-763. 10.1016/0092-8674(91)90383-A, 1904009.
8. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, Gulden H, Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 1991, 65:737-752. 10.1016/0092-8674(91)90382-9, 1904008.
9. Haupt Y, Bath ML, Harris AW, Adams JM. bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene 1993, 8:3161-3164.
10. Alkema MJ, Jacobs H, van Lohuizen M, Berns A. Pertubation of B and T cell development and predisposition to lymphomagenesis in Emu Bmi1 transgenic mice require the Bmi1 RING finger. Oncogene 1997, 15:899-8910. 10.1038/sj.onc.1201262, 9285685.
11. Bea S, Tort F, Pinyol M, Puig X, Hernández L, Hernández S, Fernandez PL, van Lohuizen M, Colomer D, Campo E. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 2001, 61:2409-2412.
12. van Galen JC, Muris JJ, Oudejans JJ, Vos W, Giroth CP, Ossenkoppele GJ, Otte AP, Raaphorst FM, Meijer CJ. Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL. J Clin Pathol 2007, 60:167-172. 10.1136/jcp.2006.038752, 16837630.
13. Mihara K, Chowdhury M, Nakaju N, Hidani S, Ihara A, Hyodo H, Yasunaga S, Takihara Y, Kimura A. Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Blood 2006, 107:305-308. 10.1182/blood-2005-06-2393, 16160010.
14. Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, Borner MM, van Lohuizen M, Betticher DC. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 2001, 84:1372-1376. 2363629, 11355949, 10.1054/bjoc.2001.1791.
15. Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK, Choe IS, Choe YK, Kim JW. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 2004, 203:217-224. 10.1016/j.canlet.2003.07.009, 14732230.
16. Kim JH, Yoon SY, Jeong SH, Kim SY, Moon SK, Joo JH, Lee Y, Choe IS, Kim JM. Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast 2004, 13:383-388. 10.1016/j.breast.2004.02.010, 15454193.
17. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, Fu LW, Huang WL, Dimri GP, Band V, Zeng YX. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006, 66:6225-6232. 10.1158/0008-5472.CAN-06-0094, 16778197.
18. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from- cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005, 115:1503-1521. 1136989, 15931389, 10.1172/JCI23412.
19. Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006, 5:1886-1901.
20. Dimri GP, Martinez JL, Jacobs JJ, Keblusek P, Itahana K, Van Lohuizen M, Campisi J, Wazer DE, Band V. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 2002, 62:4736-4745.
21. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999, 397:164-168. 10.1038/16476, 9923679.
22. Itahana K, Zou Y, Itahana Y, Martinez JL, Beausejour C, Jacobs JJ, van Lohuizen M, Band V, Campisi J, Dimri GP. Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol Cell Biol 2003, 23:389-401. 140680, 12482990, 10.1128/MCB.23.1.389-401.2003.
23. Planchon SM, Waite KA, Eng C. The nuclear affairs of PTEN. J Cell Sci 2008, 121:249-53. 10.1242/jcs.022459, 18216329.
24. Groszer M, Erickson R, Scripture-Adams DD, Lesche R, Trumpp A, Zack JA, Kornblum HI, Liu X, Wu H. Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Science 2001, 294:2186-2189. 10.1126/science.1065518, 11691952.
25. Horikawa I, Cable PL, Afshari C, Barrett JC. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 1999, 59:826-830.
26. Tang D, Okada H, Ruland J, Liu L, Stambolic V, Mak TW, Ingram AJ. Akt is activated in response to an apoptotic signal. J Biol Chem 2001, 276:30461-30466. 10.1074/jbc.M102045200, 11399756.
27. Li Y, Wu D, Chen B, Ingram A, He L, Liu L, Zhu D, Kapoor A, Tang D. ATM activity contributes to the tumor suppressing functions of p14ARF. Oncogene 2004, 23:7355-7365. 10.1038/sj.onc.1207957, 15258567.
28. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 2004, 118:409-418. 10.1016/j.cell.2004.08.005, 15315754.
29. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998, 95:5246-5250. 20246, 9560261, 10.1073/pnas.95.9.5246.
30. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Aca Sci USA 1999, 96:4240-4245.
31. Chung JH, Ginn-Pease ME, Eng C. Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein. Cancer Res 2005, 65:4108-4116. 10.1158/0008-5472.CAN-05-0124, 15899801.
32. Fan C, He L, Kapoor A, Gillis A, Rybak AP, Cutz JC, Tang D. Bmi1 promotes prostate tumorigenesis via inhibiting p16(INK4A) and p14(ARF) expression. Biochim Biophys Acta 2008, 1782:642-648.
33. Bernard D, Martinez-Leal JF, Rizzo S, Martinez D, Hudson D, Visakorpi T, Peters G, Carnero A, Beach D, Gil J. CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene 2005, 24:5543-5551. 10.1038/sj.onc.1208735, 15897876.
34. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947. 10.1126/science.275.5308.1943, 9072974.
35. Myers MP, Pass I, Batty IH, Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 1998, 95:13513-13518. 24850, 9811831, 10.1073/pnas.95.23.13513.
36. Simpson L, Parsons R. PTEN: life as a tumor suppressor. Exp Cell Res 2001, 264:29-41. 10.1006/excr.2000.5130, 11237521.
37. Gil A, Andrés-Pons A, Fernández E, Valiente M, Torres J, Cervera J, Pulido R. Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs. Mol Biol Cell 2006, 17:4002-4013. 1556382, 16807353, 10.1091/mbc.E06-05-0380.
38. Li Y, He L, Bruce A, Parihar K, Ingram A, Liu L, Tang D. p14ARF inhibits the growth of p53 deficient cells independently of Mdm2 and E2F1. Biochimica et Biophysica Acta 2006, 1763:787-796.
39. Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, Yung WK, Steck PA. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 1999, 59:2551-2556.
40. Davies MA, Kim SJ, Parikh NU, Dong Z, Bucana CD, Gallick GE. Adenoviral-mediated Expression of MMAC/PTEN Inhibits Proliferation and Metastasis of Human Prostate Cancer Cells. Clin Cancer Res 2002, 8:1904-1914.
41. Abate-Shen C, Shen MM. Molecular genertics of prostate cancer. Genes Dev 2000, 14:2410-2434. 10.1101/gad.819500, 11018010.
42. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, Yin Y. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007, 128:157-170. 10.1016/j.cell.2006.11.042, 17218262.
43. Jacob AI, Romigh T, Waite KA, Eng C. Nuclear PTEN levels and G2 progression in melanoma cells. Melanoma Res 2009, 19:203-10. 10.1097/CMR.0b013e32832ccd6e, 19478684.
44. Lin PY, Fosmire SP, Park SH, Park JY, Baksh S, Modiano JF, Weiss RH. Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. Mol Cancer 2007, 6:16. 1803787, 17300726, 10.1186/1476-4598-6-16.
45. Whiteman DC, Zhou XP, Cummings MC, Pavey S, Hayward NK, Eng C. Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer 2002, 99:63-7. 10.1002/ijc.10294, 11948493.
46. Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomäki P, de la Chapelle A, Aaltonen LA, Eng C. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol 2002, 161:439-47. 1850747, 12163369.
47. Waite KA, Eng C. Protean PTEN: Form and Function. Am J Hum Genet 2002, 70:829-844. 379112, 11875759, 10.1086/340026.
48. Abubaker J, Bavi P, Al-Haqawi W, Jehan Z, Munkarah A, Uddin S, Al-Kuraya KS. PIK3CA alterations in Middle Eastern ovarian cancers. Mol Cancer 2009, 8:51. 2724395, 19638206, 10.1186/1476-4598-8-51.
49. Chapman EJ, Kelly G, Knowles MA. Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells. Mol Cancer Res 2008, 6:1154-68. 10.1158/1541-7786.MCR-07-2168, 18644980.
50. Ruiz i Altaba A, Brand AH. Entity versus property: tracking the nature, genesis and role of stem cells in cancer. Conference on Stem cells and cancer. EMBO Rep 2009, 10:832-6. 10.1038/embor.2009.169, 19609320.
51. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, Cordon-Cardo C, Pandolfi PP. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003, 1:E59. 270016, 14691534, 10.1371/journal.pbio.0000059.
52. Wu D, Chen B, Parihar K, He L, Fan C, Zhang J, Liu L, Gillis A, Bruce A, Kappor A, Tang D. ERK activity facilitates activation of the S-phase DNA damage checkpoint by modulating ATR function. Oncogene 25:1153-1164. 10.1038/sj.onc.1209148, 16186792.